

CURRICULUM VITAE

Mark Stephen Avila, MD, MBA, FACG, AGAF

**Wellness Clinical Research
1901 SW 1 St., Second Floor
Miami, FL 33135**

PERSONAL INFORMATION

Place of Birth: San Pedro, California
Professional Address: Center for Digestive Medicine PLLC
7887 N. Kendall Drive, Suite 101
Miami, FL 33156
(305) 273-6266 Tel.
(305) 273-6520 Fax
Email Address: MSAinMIA@aol.com

PRESENT ACADEMIC RANK AND POSITION

Chairman
Probable Cause Panel South
Board of Medicine
2012- Present

Voluntary Assistant Professor of Medicine
University of Miami School of Medicine
2018-Present

Voluntary Adjunct Professor
Department of Medicine
FIU Herbert Wertheim College of Medicine
Office of International Affairs
2016-Current

Associate Clinical Instructor Hepatology
Larkin Community GI Fellowship
2018-Present

Mark Stephen Avila, M.D.
Curriculum Vitae
Page 1 of 8

Mark Avila MD
12/1/2022

EDUCATION

**University: University of Southern California
College of Letters, Arts and Sciences
Bachelor of Science,
09/1977-06/1981**

**University of Miami
School of Business Administration
MBA Executive Program
01/2011-12/2012**

**Medical School: Medical College of Wisconsin
Doctor of Medicine
08/1981-05/1985**

**Residency: Tucson Hospitals Medical Education Program
Categorical Medicine
07/1985-06/1988**

**Private Practice: Locum Tenens Internal Medicine,
07/1988-06/1990**

**Fellowship: University of Miami
Division of Hepatology
07/1990-06/1992**

**Fellowship: University of Florida
Health Sciences Campus
Division of Gastroenterology,
07/1992-06/1994**

**Master University of Miami
Executive MBA
01/2011-12/2012**

BOARD CERTIFICATION

**Federation Licensing Examination
Issued August 22, 1986**

**American Board of Internal Medicine
September 1993 (currently not certified)
Certificate Number 117938**

**American Board of Internal Medicine
Subspecialty of Gastroenterology
November 1998
Certificate Number 117938**

Re-certified 2019

MEDICAL LICENSURE

**Florida ME0054241
California A 45030**

HONORS & AWARDS

**Outstanding Fellow of the Year, 1993-1994
University of Florida- Gastroenterology
American College of Gastroenterology / Merck Scholar Award**

**Outstanding Abstract, 1992
Scholarship-Harvard Health Professions Program, 1981
Latinos for Health Careers- Senior President Award of Recognition
University of Southern California, 1981**

Resident Honors Award and Scholarship- early entrance to USC, 1976

PREVIOUS PROFESSIONAL POSITIONS & APPOINTMENTS

**Clinical Skills Community Preceptor
University of Miami School of Medicine, 1998**

Non Par Staff Physician
Veterans Administration Medical Center-Miami
Division of Hepatology, 1999
Speakers Bureau-Hepatitis C
Schering Oncology Biotech Division
Schering Pharmaceuticals, 1998
Speaker Bureau Roche Pharmaceuticals, 2001

EDUCATION-TEACHING

Undergraduate: Pre-medical science tutor for high school
USC School of Medicine
East Los Angeles School District, 1981

Fellowship: Mechanisms of Disease Course-Hepatology
University of Miami School of Medicine, 1992

Society of Gastrointestinal Nurses Associations
Lecture "Fulminant Hepatic Failure"
Annual Meeting, 1994

**INSTITUTIONAL, DEPARTMENTAL & DIVISIONAL ADMINISTRATIVE
RESPONSIBILITIES, COMMITTEE MEMBERSHIPS & OTHER ACTIVITIES**
Latino Organization for Liver Awareness (L.O.L.A.)
Advisory Board Member-South Florida, 1998 - 2002

Pan American Hospital
Pharmacy & Therapeutics Committee, 1998

Kendall Regional Medical Center
Medical Executive-Utilization Review Committee, 2000

Kindred Hospital South Florida - Vice President Medical Staff
Kindred Hospital- Member-Medical Educative Committees, 1999-Present

Kindred Hospital South Florida
Medical Executive Committee
Vice President-2001 – 2006
President- 2019 - Present

Cedars Medical Center
Division of Gastroenterology Chairman for 2001

Cedars Medical Center
Bylaws Committee 2002

Cedars Medical Center
Medical Executive- Utilization Review Committee, 2001-2004

Mercy Hospital- Division of Gastroenterology Chairman, 2004 – 2006

Dade County Medical Association
Member-Committee in Continuing Medical Education-1999 – 2001

Dade County Medical Association
Board of Directors – District 5, 1999 – 2002
Board of Directors—Member-at- Large – 2011-2013

Florida Medical Association
Task Force Medical Insurance
Florida Board of Medicine- Member- 2002 – 2006

Vice Chairman Florida Board of Medicine- 2006

PROFESSIONAL & SOCIETY MEMBERSHIPS

American College of Gastroenterology, Fellow
American Gastroenterology Association, Fellow
Dade County Medical Association
Florida Medical Association- Past

INTRAMURAL PRESENTATION

Grand Rounds, November 1994
University of Florida Health Sciences Campus
"Fulminant Hepatic Failure"
Numerous Round Table Dinner Meetings – Hepatitis C
Hepatitis C Update
Schering Plough- Speaker

CLINICAL PRACTICE, INTERESTS & ACCOMPLISHMENTS

All facets of Gastroenterology, with an emphasis on Hepatology.
Fully trained in Diagnostic Peritoneoscopy

RESEARCH INTERESTS

Active in clinical trials using therapy for Hepatitis C and Gastroenterology

COMMUNITY ACTIVITIES

Hepatitis C Support Group, Hepatitis C Alert, 1998-1999
University of Miami School of Medicine
Keys Health Fair, February 2000
Television Appearance- American Health Network
"Hepatitis C," March 11, 1999
Television Appearance-"Miami Ahora," WLTV, Univision
"Hepatitis C"

RESEARCH EXPERIENCE

2002

A Comparative Efficacy and Safety Study of NEXIUM (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Rantidine (150 mg bid) for the Healing of NSAID-associated Gastric Ulcers When Daily NSAID Use is Continued

2002

A Comparative Efficacy and Safety Study of NEXIUM (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated with Daily NSAID Use in Patients at Risk

2002

A double blind, randomized, placebo-controlled, dose ranging (5mg, 10mg, placebo) study to assess safety, efficacy, and tolerance of TAK-370 in subjects with GERD with predominant regurgitation.

2003

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with Esomeprazole Magnesium (40mg qd) to Lansoprazole (30 mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis

2003

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment with Esomeprazole 20 mg and Lansoprazole 15 mg for 6 months in Patients whose EE Has been Healed

2003

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd and 40 mg Placebo qd in Patients with Heartburn and Sleep Disturbance Associated with Gastroesophageal Reflux Disease (GERD)

2003

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd and 40 mg Placebo qd for the Resolution of Upper Abdominal Pain in Patients with Symptomatic Gastroesophageal Reflux Disease (GERD)

Mark Stephen Avila, M.D.

Curriculum Vitae

Page 7 of 8

2003

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) in Patients With Mild to Moderate Ulcerative Colitis

2004

AstraZeneca: A randomized, double-blind, multicenter study comparing a medication to placebo in the treatment of irritable bowel syndrome (IBS) symptoms.

2004

Targacept: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of a medication administered as an enema for treatment of active mild-to-moderate distal ulcerative colitis.

2004

AstraZeneca: A 4-week, randomized, double-blind, multicenter, dose-finding phase IIB study with a medication, given orally once daily for the treatment of GERD without erosive esophagitis according to the LA classification in adult subjects.

2004

AstraZeneca: A randomized, double-blind, multicenter, dose-finding Phase IIB study for up to 8 weeks treatment with a medication, given orally once daily for the healing of erosive esophagitis in adult subjects with GERD with erosive esophagitis according to the LA classification in adult subjects.

2004

Novartis: A 6-week, randomized, double-blind, placebo-controlled, multicenter study, to assess the efficacy and safety of a medication and placebo in female patients with dyspepsia.

2004

Yamanouchi Pharma America: A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study of a medication in subjects with functional dyspepsia.